Ukr.Biochem.J. 2025; Volume 97, Issue 5, Sep-Oct, pp. 139-169

About the Department of Molecular Immunology, or why it is important to study immunological processes at the molecular level

10.11.2025   Uncategorized

S. V. Komisarenko, S. I. Romaniuk

Palladin Institute of Biochemistry, National Academy of Sciences of Ukraine,
Department of Molecular Immunology, Kyiv;
e-mail: svk@biochem.kiev.ua

Received:  26 August 2025; Revised: 03 October 2025; Accepted: 30 October 2025

This review summarizes the scientific accomplishments of the Department of Molecular Immunology at the Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine over the period 1975–2025. Particular attention is given to studies on the mechanisms and functions of nicotinic acetylcholine receptors (nAChRs) expressed in lymphocytes, focusing on their role in inflammatory processes, including those associated with Alzheimer’s disease, COVID-19 and post-COVID syndrome. The review also covers research on the mathematical modeling of interactions between polyreactive immunoglobulins (PRIGs) and antigens, as well as studies on the biological functions of these antibodies. Additionally, it examines the antigenic, immunogenic, and immunobiological properties of proteins – especially recombinant proteins – that could serve as key components of diagnostic test systems and next-generation vaccines for respiratory infectious diseases such as pertussis, diphtheria, tuberculosis and COVID-19. The article further considers opportunities to develop therapeutic agents based on recombinant proteins, including single-chain variable fragment (including scFv antibodies), vitamin complexes and other bioactive components for the treatment of human diseases. Special attention is also given to efforts aimed at disseminating knowledge on biosafety, bioprotection and bioethics in Ukraine. Finally, the review looks at future prospects for the Department of Molecular Immunology, in light of current challenges and new opportunities, particularly those arising from rapid advances in biotechnology.

Keywords: , , , , , , , ,

References:

  1.  Palladin Institute of Biochemistry of the NAS of Ukraine – 80, 1925–2005: On the 120th anniversary of Academician O. V. Palladin / Editor-in-Chief S.V. Komisarenko. K: Alpha-Prime, 2005. 496 p. (In Ukrainian).
  2. Butenko ZA, Zak KP, Komissarenko SV, Gruzov MA, Khomenko BM. Immunoelectron microscopy of the bone marrow mononuclears labelling with rabbit anti­mouse brain serum using peroxidase­anti­peroxidase method. Blut. 1983; 47(6): 343­349.
  3. Komisarenko SV. Horseradish peroxidase: properties and application in neuro­enzyme assay / Axonal transport of substances in brain systems. K.: Nauk. Dumka, 1981, 153­161.
  4. Gula NM, Komisarenko SV. Inorganic pyrophosphate, its structural analogs and inorganic pyrophosphatase. Uspechi Biol Khimii. 1982; 22: 195­213.
  5. Pat. 12053 UA 4IPC С07F 9/38, A61K 31/66. Dihydrate disodium salt of methylene bisphosphonic acid exhibits antitumor activity. Komisarenko SV, Karlova NP, Sharykina NI, Kudryavtseva IG, Iezerska LI, Lozynskyi MO, Borisevich AN, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine; Institute of Organic Chemistry, NAS of Ukraine; Institute of Pharmacology and Toxicology, NAMS of Ukraine, No 4239930 SU; appl. 23.03.87; publ. 25.12.96. Bul. No 4.
  6. Pat. 40714 А UА 7 С01В15/16, А61K 31/327. Antitumor therapeutic drug (MEBIFON). Komisarenko SV, Sharykina NI, Lozynskyi MO, Karlova NP, Kudryavtseva IG, Kuzmenko IY, Borisevich AN, Iezerska LI, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine; Institute of Pharmacology and Toxicology, NAMS of Ukraine; Institute of Organic Chemistry, NAS of Ukraine, No 2001074659; appl. 04.07.01; publ. 15.08.01, Bul. No 7.
  7. Pat. 12056 А UА. Method for obtaining labeled antibodies. Komisarenko SV, Fomovska GN, Levchuk OP, Borisevich AN, Lozynskyi MO, Mirian NI, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine; Institute of Organic Chemistry, NAS of Ukraine, No 4395425 SU, appl. 09.02.88; publ. 25.12.96, Bul. No 4.
  8. Pat. 12055 UА 4 С08K 5/53, С08G 18/06. Polyurethane composition. Komisarenko SV, Karlova NP, Fomovska GN, Borisevich AN, Lozynskyi MO, Pkhakadze GA, appl. 25.12.84, publ. 25.12.96, Bul. No 4.
  9. Danilova VM, Vynogradova RP, Torkhova SG. Inventive activity of the Department of Molecular Immunology of the Palladin Institute of Biochemistry of NAS of Ukraine. Ukr Biochem J. 2016; 88(5): 116-135. (In Ukrainian).
  10. Komisarenko SV, Vasilieva GA, Evstigneeva RP. Immunochemical analysis of equine cytochrome C. Stoichiometry of the interaction and cytochrome C affinity for specific Fab fragments. Dokl Akad Nauk SSSR. 1982; 264(3): 752­755. (In Russian).
  11. A.C. 1379739 SU, 4 IPC G01 No 33/49. Method for prognosis of complicated course of myocardial infarction. Komisarenko SV, Skok MV, Gvatua NA, Solonenko IN, Piven VI, (SU) appl. 27.01.86; publ. 07.03.88, Bul. No 9.
  12. Komisarenko SV My path in life and in science. Report on the occasion of awarding V.I. Vernadsky Gold Medal of NAS of Ukraine. Visnyk NAS of Ukraine. 2024; 5: 72-78. (In Ukrainian).
  13. Radiation and human immunity: The effect of low doses of radiation resulting from the Chernobyl accident on cells of the human hematopoietic and immune systems / Ed. by Komissarenko SV, Zak KP. Kyiv: Naukova Dumka, 1994. 112 p. (In Russian).
  14. Lugovskoy EV, Makogonenko EM, Chudnovets VS, Derzskaya SG, Gogolinskaya GK, Kolesnikova IN, Bukhanevich AM, Sitak IN, Lyashko ED, Komissarenko SV. The study of fibrin polymerization with monoclonal antibodies. Biomed Sci. 1991; 2(3): 249­256.
  15. Lugovskoy EV, Chudnovets VS, Makogo­nenko EM, Derzskaia SG, Gogolinskaia GK, Kolesnikova IN, Mikhalovskaia LI, Komissarenko SV. Study of the polymerization of fibrin using monoclonal antibodies 2D­2A and their Fab­fragments. Ukr Biokhim Zhurn. 1995; 67(1): 64­70. (In Russian).
  16. Lugovskoy EV, Komisarenko SV. Monoclonal antibodies as an instrument to study fibrin polymerization. Bioorg Khim. 2000; 26(12): 883­891. (In Russian).
  17. Pat. 73232 UA 7IPC С12N5/18, С12Р21/08. Strain of animal hybridoma cells Mus musculus L. – producing monoclonal antibodies that specifically react with N­terminal epitope of γ­chain of human fibrin D­dimer and fibrinogen D­fragment. Komisarenko SV, Kolesnikova IM, Lugovskoy EV, Liashko KD, Litvinova LM, Kostiuchenko OP, Gogolinska GK, Gritsenko PG, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No 2003077105; appl. 28.07.03; publ.15.06.05, Bul. No 6.
  18. Pat. 73233 UA 7IPC C12N5/18, С12P21/08. Strain of animal hybridoma cells Mus musculus L. – producing specific monoclonal antibodies to N­terminal epitope of human fibrinogen Bβ-chain. Komisarenko SV, Kolesnikova IM, Lugovskoy EV, Liashko KD, Litvinova LM, Kostiuchenko OP, Gogolinska GK, Gritsenko PG, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No 2003077106; appl. 15.06.05; publ. 15.06.05, Bul. No 6.
  19. Pat. 73823 UA 7IPC С12N5/12, С12N5/18, С12N5/20. Strain of animal hybridoma cells Mus musculus L. which are cultivated and produce specific monoclonal antibodies to human fibrin D­dimer. Komisarenko SV, Kolesnikova IM, Lugovskoy EV, Liashko KD, Litvinova LM, Kostiuchenko OP, Gogolinska GK, Gritsenko PG, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No 2003076213; appl. 04.07.03; publ. 15.09.05, Bul. No 9.
  20. Pat. 87375 UA IPC (2009) С12N 5/20, C07K 16/36 (2009.01). Strain of animal hybridoma cells Mus musculus L. which are cultivated and produce specific monoclonal antibodies to human fibrin. Komisarenko SV, KolesnikovaIM, Lugovskoy EV, Liashko KD, Gritsenko PG, Litvinova LM, Kostiuchenko OP, Lugovska NE, Gogolinska GK, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No а200712284; appl. 06.11.2007; publ. 10.07.2009, Bul. No 13.
  21. Pat. 69283 U UA, IPC А 61K 39/44 (2006.01). Immunoenzyme test­system for quantitative determination of soluble fibrin in human blood plasma. Komisarenko SV, Lugovskoy EV, Kolesnikova IM, Spivak MY, Gritsenko PG, Ganova LO, Lugovska NE, Litvinova LM, Liashko KD, Kostiuchenko OP, Pozniak TA, Gogolinska GK, Kovtoniuk GV, TereschenkoMI, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, No u201111736; appl. 05.10.2011; publ. 25.04.2012, Bul. No 8.
  22. Pat. 69284 U UA IPC А 61K 39/44 (2006.01). Immunoenzyme test­system for quantitative determination of D­dimer in human blood plasma. Komisarenko SV, Lugovskoy EV, Kolesnikova IM, Spivak MY, Gritsenko PG, Ganova LO, Lugovska NE, Litvinova LM, Liashko KD, Kostiuchenko OP, Pozniak TA, Gogolinska GK, Kovtoniuk GV, TereschenkoMI, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine; Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, No u201111736; appl. 05.10.2011; publ. 25.04.2012, Bul. No 8.
  23. Pat. 70456 U UA, IPC А 61K 39/44 (2006.01). Immunoenzyme test­system for quantitative determination of fibrinogen in human blood plasma. Komisarenko SV, Lugovskoy EV, Kolesnikova IM, Spivak MY, Gritsenko PG, Ganova LO, Lugovska NE, Litvinova LM, Liashko KD, Kostiuchenko OP, Pozniak TA, Gogolinska GK, Kovtoniuk GV, Tereschenko MI, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine; Zabolotny Institute of Microbiology and Virology, NAS of Ukraine, No u201114516; appl. 07.12.2011; publ. 11.06.2012, Bul. No 11.
  24. “We are optimistic about the future…”: interview with S. Komissarenko, academician of the NAS of Ukraine, director of the Palladin Institute of Biochemistry of the NAS of Ukraine. Nauka ta Naukoznavstvo. 2025; 2(128): 3-26. (In Ukrainian).
  25. Wiker HG, Lyashchenko KP, Aksoy AM, Lightbody KA, Pollock JM, Komissarenko SV, Bobrovnik SO, Kolesnikova IN, Mykhalsky LO, Gennaro ML, Harboe M. Immunochemical characterization of the MPB70/80 and MPB83 proteins of Mycobacterium bovis. Infect Immun. 1998; 66(4): 1445­1452.
  26. Bobrovnik SA, Demchenko MO, Komisarenko SV. Effect of trifluoroethanol on antibody reactivity against corresponding and nonrelated antigens. Ukr Biochem J. 2018; 90(4): 80-89.
  27. Bobrovnik SA, Demchenko MO, Komisarenko SV. Kinetics of interaction between polyreactive immunoglobulins and antigen. The theory. Ukr Biochem J. 2019; 91(4): 88-94.
  28. Bobrovnik SA, Ogloblya OV, Demchenko MO, Komisarenko SV. Thermodynamics of interaction between polyreactive immunoglobulins and immobilized antigen. Ukr Biochem J. 2021; 93(5): 82-89.
  29. Bobrovnik SA, Demchenko MO, Komisarenko SV. Effect of trifluoroethanolon antibodies binding properties. Ukr Biochem J. 2023; 95(1): 20-30.
  30. Kramarev SA, Litvinenko NG, Buts AR, Kavun EM, Kolybo DV, Romaniuk SI, Dzhedzhula GG, Radavskyi YL, Komisarenko SV. The importance of detecting toxins in the blood in cases of diphtheria infection in children. Lab Diagnost. 1998; 3: 21-24. (In Russian).
  31. Labyntsev AIu, Korotkevych NV. Manoilov KJ, Kaberniuk AA, Kolibo DV, Komisarenko SV. Recombinant fluorescent models for studying the diphtheria toxin. Bioorg Khim. 2014; 40(4): 433­442. (In Russian).
  32. Pat. 84356 UА IPC (2006) А61K 39/44, А61K47/48, С07К 7/08 (2006.01); С12N 15/11. Esherichia coli K12 “INV” sbA strain – producing recombinant non­active A subunit of diphtheria toxin Corynebacterium diphtheria hybridized with polyhistidine tag. Komisarenko SV, Kolibo DV, Romaniuk SI, Kaberniuk AA, Oliinyk OS, Redchuk TA, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No а200701085; appl. 02.02.2007; publ. 10.10.2008, Bul. No 19.
  33. Pat. 84357 UА IPC (2006) А61K 39/44, А61K47/48, С07К 7/08 (2006.01); С12N 15/11. Esherichia coli К12 “IINV” sbВ strain producing recombinant non­active B subunit of diphtheria toxin Corynebacterium diphtheria hybridized with polyhistidine tag. Komisarenko SV, Kolibo DV, Romaniuk SI, Kaberniuk AA, Oliinyk OS, Redchuk TA, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No а20070108; appl. 02.02.2007; publ. 10.10.2008, Bul. No 19.
  34. Romaniuk SI, Kolybo DV, Kavun EM, Radavskyi YL, Tkachenko TY, Kramarev SA, Komisarenko SV. Specificity of antibodies to diphtheria toxin subunits in children with various diagnoses. Ukr Biochem J. 2001; 73(6): 73-76. (In Russian).
  35. Kulyk YaS, Siromolot AA, Kolybo DV. Epitopes identification of broadly neutralizing monoclonal antibodies against Corynebacterium diphtheriae exotoxin. Biotechnol Acta. 2022; 15(4): 34-37.
  36. Oliinyk OS, Kaberniuk AA, Burkaleva DO, Romaniuk SI, Kolibo DV, Shepelyakovskaya AO, Laman AG, Komisarenko SV Obtaining of recombinant scFv-antibodies against diphtheria toxin using phage display system. Ukr Biochem J. 2007; 79(5): 91-97.
  37. Korotkevich NV, Kolibo DV, Labyntsev АJ, Romaniuk SІ, Komisarenko SV. Obtaining of recombinant human heparin binding EGF­like growth factor and perspectives of its application in biotechnology. Biotechnol Acta. 2010; 3(4): 44­54.
  38. Korotkevych NV, Labyntsev AJ, Kolybo DV, Komisarenko SV. The soluble heparin-binding EGF-like growth factor stimulates EGF receptor trafficking to the nucleus. PLoS One. 2015; 10(5): e0127887.
  39. Krynina OI, Manoilov KYu, Kolybo DV, Komisarenko SV. Role of the heparin-binding domain in intracellular trafficking of sHB-EGF. Ukr Biochem J. 2019; 91(4): 26-32.
  40. Krynina OI, Korotkevych NV, Labyntsev AJ, Romaniuk SI, Kolybo DV, Komisarenko SV. Influence of human HB-EGF secreted form on cells with different EGFR and ErbB4 quantity. Ukr Biochem J. 2019; 91(5): 25-33.
  41. Vovk I, DidanA, Zhukova D, Dronko L, Rebriev A, Rybalko A, Legach E, Gorbatiuk O, Usenko M, Skvarchynskyi A, Dovbymchuk T, Siromolot A, Romaniuk S, Kolybo D. Production and in vitro evaluation of recombinant human HB-EGF for wound healing and targeted therapy. Biotechnol Acta. 2025; 18(1): 55-66.
  42. Dronko LM, Lutsenko TM, Golembiovska OI, Trokhymchuk TYu, Arkhypova MA, Dibrova VA, Dibrova YuV, Rybalko SL, Myakushko SA, Siromolot AA, Galkin OYu. Efficacy of human heparin-binding EGF-like growth factor in healing experimental chemical burns. Ukr Biochem J. 2025; 97(2): 31-40.
  43. Siromolot AA, Krynina OI, Kolybo DV, Komisarenko SV. Antiproliferative and apoptotic effects of anti-human HB-EGF neutralizing polyclonal antibodies in vitro. Exp Oncol. 2020; 42(1): 25-30.
  44. Zhukova D, Katashynska D, Siromolot A, Romaniuk S, Kolybo D, Komisarenko S. Nontoxic diphtheria toxin derivates CRM197 and B-fragment can serve as the means for targeted curcumin delivery into sensitive cancer cells. J Drug Deliv Sci Technol. 2024; 96: 105673.
  45. Chudina T, Labyntsev A, Manoilov K, Kolibo D, Komisarenko S. Cellobiose-coated poly (laсtide-co-glycolide) particles loaded with diphtheria toxoid for per os immunization. Croat Med J. 2015; 56(2): 85­93.
  46. Redchuk TA, Oliinyk OS, Kaberniuk AA, Burkalieva DO, Romaniuk SI, Kolibo DV, Komisarenko SV. Cloning and expression of proteins Mycobacterium bovis MPB63 and MPB83 in Escherichia coli cells. Rep Nat Acad Sci Ukraine. 2007; (9): 161­166.
  47. Siromolot AA, Kolibo DV. Putative target cells for Mycobacterium tuberculosis antigens MPT63 and MPT83. Res J Pharm Biol Chem Sci. 2018; 9(2): 367-378.
  48. Redchuk TA, Korotkevich NV, Kaberniuk AA, Oliinyk OS, Labyntsev AJ, Romaniuk SI, Kolibo DV, Komisarenko SV. Recombinant chimera protein MPB63–MPB83 as perspective antigen for diagnostics of tuberculosis. Biotechnology. 2010; 3(5): 50­56.
  49. Pat. 100065 U UA, IPC G01N 33/49 (2006.01), G01N 33/53 (2006.01), G01N 33/531 (2006.01). Immunoenzyme test­system for detection of antibodies to Mycobacterium bovis. Komisarenko SV, Kolibo DV, Oliinyk OS, Redchuk TA, Lugovska NE, Siromolot AA, Stegnii BT, Gerilovych AP, Zavgorodnii AI, Nikolaenko IV, Raievska GE, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, No u201413675; appl. 19.12.2014; publ. 10.07.2015, Bul. No 13.
  50. Pat. 118447 UA, IPC (2017.01) А61В10/00, G01N 33/49 (2006.01), G01N 33/53 (2006.01), G01N 33/531 (2006.01). Immunoenzyme test-system for detecting antibodies to Mycobacterium tuberculosis / Komisarenko SV, Kolybo DV, Redchuk TA, Oliinyk OS, Galkin OY, Romaniuk SI, 51. Siromolot AA, Lugovska NE, Feschenko YI, Rekalova EM, Chudina TO, applicant and patent owner: Palladin Institute of Biochemistry, NAS of Ukraine, – No u 2017 01655; appl. 21.02.2017; publ. 10.08.2017, Bul.No 15.
  51. Siromolot AA, Chudina TO, Danilova IS, Rekalova EM, Kolybo DV, Komisarenko SV. Specificity and sensitivity of the new test for serological evaluation of tuberculosis using MPT83-MPT63 fusion antigen and factors affecting testing. Ukr Biochem J. 2018; 90(6): 41-48.
  52. Rekalova O, Panasiukova O, Pogrebna M, Yasir S, Siromolot A, Romaniuk S, Kolybo D, Komisarenko S, Feschenko Y. Detection of specific antibodies using MPT83-MPT63 fusion protein in patients with destructive pulmonary tuberculosis. Proc Shevchenko Sci Soc Med Sci. 2022; 69(2): 40-49.
  53. Krynina OI, Romaniuk SI, Gorbatiuk OB, Korchynskyi OH, Rebriiev АV, Kulyk YaS, Kozadaieva YeO, Siromolot AA, Guzyk MM, Kolybo DV, Komisarenko SV. Production of recombinant SARS-CoV-2 proteins and diphtheria toxoid CRM197-based fusion. Ukr Biochem J. 2021; 93(6): 31-45.
  54. Komisarenko SV On the participation of scientists of the NAS of Ukraine in counteracting COVID-19. Development of vaccines against SARS-CoV-2 and COVID-19 in Ukraine: Status, problems and prospects: Transcript of report at the meeting of the Presidium of NAS of Ukraine, June 9, 2021. Visnyk NAS of Ukraine. 2021; 8: 51-55. (In Ukrainian).
  55. Komisarenko SV. The World Coronavirus Crisis/ SV Komisarenko. Kyiv, 2020. ISBN 978-617-7824-26-7 (In Ukrainian).
  56. Lykhmus O, Kalashnyk O, Koval L, Krynina O, Komisarenko S, Skok M. Immunization with 674-685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice. Biochem Biophys Res Commun. 2022; 622: 57-63.
  57. Skok MV. Cholinergic mechanisms of neuroinflammation and neurodegeneration development. Transcript of scientific report at the meeting of the Presidium of NAS of Ukraine, September 7, 2022. Visnyk NAS of Ukraine. 2022; 11: 17-22. (In Ukrainian).
  58. Romaniuk SI, Tykhonenko TM, Siromolot AA, Guzyk MM, Lugovska NE, Galkin OYu, Kuchmerovska ТМ, Kolybo DV, Komisarenko SV. Development of a dietary supplement for improving the cognitive functions and lowering the homocysteine levels. Sci Innov. 2022; 18(1): 66-75.
  59. Volodina TT, Korotkevich NV, Romaniuk SI, Galkin OYu, Kolybo DV, Komisarenko SV. Implementation of dietary supplements with effect of dezintoxication and improvement of osteogenesis and metabolism. Sci Innov. 2017; 13(6): 39-50.
  60. Skok MV, Koval LM, Lykhmus OYu., Kalashnyk JM, Gergalova GL, Komisarenko SV. Nicotinic acetylcholine receptors: specific antibodies and function in humoral immunity. Ukr Biochem J. 2013; 85(6):134­143.
  61. Palladin Institute of Biochemistry, NAS of Ukraine / Ed. by Komisarenko SV. K.: Publisher: FOP Moskalenko O.M,2015. 192 p. ISBN 978-966-2214-62-8 (In Ukrainian).
  62. Kalashnyk O, Lykhmus O, Uspenska K, Izmailov M, Komisarenko S, Skok M. Mitochondrial α7 nicotinic acetylcholine receptors are displaced from complexes with VDAC1 to form complexes with Bax upon apoptosis induction. Int J Biochem Cell Biol. 2020; 129: 105879.
  63. Uspenska K, Lykhmus O, Arias HR, Pons S, Maskos U, Komisarenko S, Skok M. Positive allosteric modulators of α7* or β2* nicotinic acetylcholine receptors trigger different kinase pathways in mitochondria. Int J Biochem Cell Biol. 2018; 99: 226-235.
  64. Skok M. Mitochondrial nicotinic acetylcholine receptors: mechanisms of functioning and biological significance (review). Int J Biochem Cell Biol. 2022; 143: 106138.
  65. Lykhmus O, Gergalova G, Koval L, Zhmak M, Komisarenko S, Skok M. Mitochondria express several nicotinic acetylcholine receptor subtypes to control various pathway of apoptosis induction. Int J Biochem Cell Biol. 2014; 53: 246­252.
  66. Lykhmus O, Voytenko L, Koval L, Mykhalskiy S, Knolin V, Peschana R, Zouridakis M, Tzartor S, Komisarenko S, Skok M. α7 Nicotinic acetylcholine receptor – specific antibody induces inflammation and amiloid β42 accumulation in the mouse brain to impair memory. PLoS One. 2015; 10(3): e 0122706.
  67. Lykhmus O, Tzeng WY, Koval L, Uspenska K, Zirdum E, Kalashnyk O, Garaschuk O, Skok M. Impairment of brain function in a mouse model of Alzheimer’s disease during the pre-depositing phase: The role of α7 nicotinic acetylcholine receptors. Biomed Pharmacother. 2024; 178: 117255.
  68. Lykhmus O, Kalashnyk O, Koval L, Krynina O, Komisarenko S, Skok M. Immunization with 674-685 fragment of SARS-Cov-2 spike protein induces neuroinflammation and impairs episodic memory of mice. Biochem Biophys Res Commun. 2022; 622: 57-63.
  69. Skok M. The role of α7 nicotinic acetylcholine receptors in post-acute sequelae of COVID-19. Int J Biochem Cell Biol. 2024; 168: 106519.
  70. Yevdokimova NYu, Wahab NA, Mason RM. Thrombospondin-1 is the key activator of TGFbeta1 in human mesangial cells exposed to high glucose. J Am Soc Nephrol. 2001; 12(4): 703-712.
  71. Yevdokimova NYu, Veselovska LD, Gogolinska GK, Buchanevich OM Kosyakova GV, Gritsenko PG, Lugovskoj EV, Komisarenko SV. Fibrin D-dimer impairs the accumulation and anticoagulant properties of heparan sulphate and stimulates plasminogen activator inhibitor-1 secretion by rabbit aortic endothelial cells. Acta Biochim Polonica. 2003; 50(1): 279-289.
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.